in this issue
Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
Biocon and Optimer Sign API Manufacturing Deal
11:08 PM MDT | May 25, 2010 | Deepti Ramesh
Biotechnology company and manufacturing services provider Biocon (Bangalore, India) says it has entered into a long-term supply agreement with biopharmaceutical company Optimer Pharmaceuticals (San Diego, CA) for the commercial manufacturing of the active pharmaceutical ingredient (API) fidaxomicin - Optimer's lead product candidate for the treatment of clostridium difficile infection (CDI). Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of CDI and Optimer has reported positive top-line results from two Phase 3 trials of...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee